Advertisement

Drugs & Aging

, Volume 29, Issue 6, pp 463–475 | Cite as

Underprescription of Beneficial Medicines in Older People

Causes, Consequences and Prevention
  • Antonio CherubiniEmail author
  • Andrea Corsonello
  • Fabrizia Lattanzio
Review Article

Abstract

Underprescription of potentially useful drugs is widespread among older people and may herald several adverse outcomes. We aimed to review the evidence pertaining to the epidemiology, causes and consequences of underprescribing, as well as recent advances in the development of interventions able to reduce underprescribing and improve outcomes in older people.

Underprescribing is highly prevalent across different settings, including in the community, hospitals and nursing homes. Multimorbidity, polypharmacy, ageism, lack of scientific evidence, fear of adverse events and economic problems may contribute to the underprescription of indicated drugs, although in some patients, a limited life expectancy, the lack of a favourable risk-to-benefit ratio or a patient’s refusal might represent appropriate reasons not to prescribe a drug.

Selected interventions may help to improve the quality of prescriptions and reduce the burden of underprescribing. Among these, comprehensive geriatric assessment (CGA) has been demonstrated to effectively improve prescribing practice. Interventions based on service delivery changes, such as those that include a clinical pharmacist or a case manager in the process of care, were also found to improve the quality of pharmacological prescriptions. Educational interventions may also be effective in reducing underprescribing.

More recently, the clinical application of the Screening Tool to Alert Doctors to Right Treatment (START) criteria has been able to significantly reduce underprescribing. Since START criteria are easier to apply in clinical practice than other instruments, it is conceivable that their systematic use may contribute to reducing underprescribing and to improving health outcomes in older patients.

Keywords

Nursing Home Resident Clinical Pharmacist Antithrombotic Therapy Comprehensive Geriatric Assessment Multiple Chronic Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Antonio Cherubini and Andrea Corsonello contributed equally to this work.

All authors declare to have no conflicts of interest regarding this manuscript. No sources of funding were used to assist in the preparation of this article.

References

  1. 1.
    Christensen K, Doblhammer G, Rau R, et al. Ageing populations: the challenges ahead. Lancet 2009 Oct 3; 374 (9696): 1196–208PubMedCrossRefGoogle Scholar
  2. 2.
    Shi S, Morike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008 Feb; 64 (2): 183–99PubMedCrossRefGoogle Scholar
  3. 3.
    Laroche ML, Charmes JP, Bouthier F, et al. Inappropriate medications in the elderly. Clin Pharmacol Ther 2009 Jan; 85 (1): 94–7PubMedCrossRefGoogle Scholar
  4. 4.
    Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005 Aug 10; 294 (6): 716–24PubMedCrossRefGoogle Scholar
  5. 5.
    Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004 Dec 30; 351 (27): 2870–4PubMedCrossRefGoogle Scholar
  6. 6.
    Cherubini A, Del Signore S, Ouslander J, et al. Fighting against age discrimination in clinical trials. J Am Geriatr Soc 2010 Sep; 58 (9): 1791–6PubMedCrossRefGoogle Scholar
  7. 7.
    Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011 Mar 28; 171 (6): 550–6PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995 Oct 9; 155 (18): 1949–56PubMedCrossRefGoogle Scholar
  9. 9.
    Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997 Aug; 45 (8): 945–8PubMedGoogle Scholar
  10. 10.
    Bootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997 Oct 13; 157 (18): 2089–96PubMedCrossRefGoogle Scholar
  11. 11.
    Schimmel EM. The hazards of hospitalization. 1964. Qual Saf Health Care 2003 Feb; 12 (1): 58–63; discussion-4PubMedCrossRefGoogle Scholar
  12. 12.
    Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995 Jul 5; 274 (1): 35–43Google Scholar
  13. 13.
    Cherubini A, Ruggiero C, Gasperini B, et al. The prevention of adverse drug reactions in older subjects. Curr Drug Metab 2011 Sep; 12 (7): 652–7PubMedCrossRefGoogle Scholar
  14. 14.
    Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22 (5): 375–92PubMedCrossRefGoogle Scholar
  15. 15.
    Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001 Feb; 49 (2): 200–9PubMedCrossRefGoogle Scholar
  16. 16.
    Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165 (7): 790–5PubMedCrossRefGoogle Scholar
  17. 17.
    Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002 Dec; 50 (12): 1962–8PubMedCrossRefGoogle Scholar
  18. 18.
    Olivier P, Bertrand L, Tubery M, et al. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey. Drugs Aging 2009; 26 (6): 475–82PubMedCrossRefGoogle Scholar
  19. 19.
    Zopf Y, Rabe C, Neubert A, et al. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Saf 2008; 31 (9): 789–98PubMedCrossRefGoogle Scholar
  20. 20.
    Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006 Mar; 4 (1): 36–41PubMedCrossRefGoogle Scholar
  21. 21.
    Kuijpers MA, van Marum RJ, Egberts AC, et al. Relationship between polypharmacy and underprescribing. Br J Clin Pharmacol 2008 Jan; 65 (1): 130–3PubMedCrossRefGoogle Scholar
  22. 22.
    Kuzuya M, Masuda Y, Hirakawa Y, et al. Underuse of medications for chronic diseases in the oldest of community-dwelling older frail Japanese. J Am Geriatr Soc 2006 Apr; 54 (4): 598–605PubMedCrossRefGoogle Scholar
  23. 23.
    Shrank WH, Asch SM, Adams J, et al. The quality of pharmacologic care for adults in the United States. Med Care 2006 Oct; 44 (10): 936–45PubMedCrossRefGoogle Scholar
  24. 24.
    Hanlon JT, Handler S, Maher R, et al. Geriatric pharmacotherapy and polypharmacy. In: Fillit H, Rockwood K, Woodhouse K, editors. Brocklehurst’s textbook of geriatric medicine. 7th ed. London: Churchill Livingstone, 2010: 880–5CrossRefGoogle Scholar
  25. 25.
    Lipton H, Bero L, Bird J, et al. Undermedication among geriatric outpatients: results of a randomized controlled trial. Ann Rev Gerontol 1992; 12: 95–108Google Scholar
  26. 26.
    Ahmed A, Allman RM, DeLong JF, et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J 2002 Jul; 95 (7): 703–10PubMedGoogle Scholar
  27. 27.
    Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch Intern Med 2000 Jan 10; 160 (1): 53–60Google Scholar
  28. 28.
    Howard PA, Shireman TI, Dhingra A, et al. Patterns of ACE inhibitor use in elderly Medicaid patients with heart failure. Am J Geriatr Cardiol 2002 Sep–Oct; 11 (5): 287–94PubMedCrossRefGoogle Scholar
  29. 29.
    Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004 Aug 10; 110 (6): 724–31PubMedCrossRefGoogle Scholar
  30. 30.
    Mendelson G, Aronow WS. Underutilization of angiotensin-converting enzyme inhibitors in older patients with Q-wave anterior myocardial infarction in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1998 Jun; 46 (6): 751–2PubMedGoogle Scholar
  31. 31.
    Allsworth JE, Toppa R, Palin NC, et al. Racial and ethnic disparities in the pharmacologic management of diabetes mellitus among long-term care facility residents. Ethn Dis 2005 Spring; 15 (2): 205–12PubMedGoogle Scholar
  32. 32.
    Dunn EJ, Burton CJ, Feest TG. The care of patients with diabetic nephropathy: audit, feedback, and improvement. QJM 1999 Aug; 92 (8): 443–9PubMedCrossRefGoogle Scholar
  33. 33.
    Hollingworth SA, Byrne GJ. Prescribing trends in cognition enhancing drugs in Australia. Int Psychogeriatr 2011 Mar; 23 (2): 238–45PubMedCrossRefGoogle Scholar
  34. 34.
    Brown MN, Lapane KL, Luisi AF. The management of depression in older nursing home residents. J Am Geriatr Soc 2002 Jan; 50 (1): 69–76PubMedCrossRefGoogle Scholar
  35. 35.
    George K, Davison TE, McCabe M, et al. Treatment of depression in low-level residential care facilities for the elderly. Int Psychogeriatr 2007 Dec; 19 (6): 1153–60PubMedCrossRefGoogle Scholar
  36. 36.
    Parikh S, Mogun H, Avorn J, et al. Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch Intern Med 2008 May 26; 168 (10): 1111–5PubMedCrossRefGoogle Scholar
  37. 37.
    Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998 Jun 17; 279 (23): 1877–82Google Scholar
  38. 38.
    Feldt KS, Gunderson J. Treatment of pain for older hip fracture patients across settings. Orthop Nurs 2002 Sep–Oct; 21 (5): 63–4, 6–71PubMedCrossRefGoogle Scholar
  39. 39.
    Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther 2008 Feb; 46 (2): 72–83PubMedGoogle Scholar
  40. 40.
    Winkelmayer WC, Fischer MA, Schneeweiss S, et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis 2005 Dec; 46 (6): 1080–7PubMedCrossRefGoogle Scholar
  41. 41.
    Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc 2006 Oct; 54 (10): 1516–23PubMedCrossRefGoogle Scholar
  42. 42.
    Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol 2004 Jun; 57 (6): 798–806CrossRefGoogle Scholar
  43. 43.
    Wright RM, Sloane R, Pieper CF, et al. Underuse of indicated medications among physically frail older US veterans at the time of hospital discharge: results of a cross-sectional analysis of data from the Geriatric Evaluation and Management Drug Study. Am J Geriatr Pharmacother 2009 Oct; 7 (5): 271–80PubMedCrossRefGoogle Scholar
  44. 44.
    Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med 2010 Dec; 21 (6): 516–23PubMedCrossRefGoogle Scholar
  45. 45.
    Lang PO, Hasso Y, Drame M, et al. Potentially inappropriate prescribing including under-use amongst older patients with cognitive or psychiatric co-morbidities. Age Ageing 2010 May; 39 (3): 373–81PubMedCrossRefGoogle Scholar
  46. 46.
    Coveney AP, O’Brien GC, Fulton GJ. ACE up the sleeveare vascular patients medically optimized? Vasc Health Risk Manag 2011; 7: 15–21PubMedCrossRefGoogle Scholar
  47. 47.
    Gallagher P, Lang PO, Cherubini A, et al. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol 2011 Nov; 67 (11): 1175–88PubMedCrossRefGoogle Scholar
  48. 48.
    Heston LL, Garrard J, Makris L, et al. Inadequate treatment of depressed nursing home elderly. J Am Geriatr Soc 1992 Nov; 40 (11): 1117–22PubMedGoogle Scholar
  49. 49.
    Lapane KL, Barbour MM, Van Haaren A, et al. Anti-ischemic therapy in patients with coronary heart disease living in long-term care. Systematic Assessment of Geriatric Drug Use by Epidemiology (SAGE) Group. Pharmacotherapy 1999 May; 19 (5): 627–34Google Scholar
  50. 50.
    Lapane KL, Fernandez HH, Friedman JH. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson’s disease in residents in long-term care facilities. SAGE Study Group. Pharmacotherapy 1999 Nov; 19 (11): 1321–7Google Scholar
  51. 51.
    Spooner JJ, Lapane KL, Hume AL, et al. Pharmacologic treatment of diabetes in long-term care. J Clin Epidemiol 2001 May; 54 (5): 525–30PubMedCrossRefGoogle Scholar
  52. 52.
    Christian JB, Lapane KL, Toppa RS. Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents. Stroke 2003 Nov; 34 (11): 2693–7PubMedCrossRefGoogle Scholar
  53. 53.
    Sloane PD, Gruber-Baldini AL, Zimmerman S, et al. Medication undertreatment in assisted living settings. Arch Intern Med 2004 Oct 11; 164 (18): 2031–7PubMedCrossRefGoogle Scholar
  54. 54.
    Hughes CM, Lapane KL. Factors associated with the initiation and discontinuation of secondary stroke prevention agents in nursing homes. J Stroke Cerebrovasc Dis 2004 Jul–Aug; 13 (4): 164–70PubMedCrossRefGoogle Scholar
  55. 55.
    Hanlon JT, Wang X, Castle NG, et al. Potential underuse, overuse, and inappropriate use of antidepressants in older veteran nursing home residents. J Am Geriatr Soc 2011 Aug; 59 (8): 1412–20PubMedCrossRefGoogle Scholar
  56. 56.
    Hayward RA, Asch SM, Hogan MM, et al. Sins of omission: getting too little medical care may be the greatest threat to patient safety. J Gen Intern Med 2005 Aug; 20 (8): 686–91PubMedCrossRefGoogle Scholar
  57. 57.
    Fahey T, Montgomery AA, Barnes J, et al. Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study. BMJ 2003 Mar 15; 326 (7389): 580PubMedCrossRefGoogle Scholar
  58. 58.
    Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997 Jan 8; 277 (2): 115–21PubMedCrossRefGoogle Scholar
  59. 59.
    Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatmentrisk paradox. JAMA 2004 Apr 21; 291 (15): 1864–70PubMedCrossRefGoogle Scholar
  60. 60.
    Flaker GC, McGowan DJ, Boechler M, et al. Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation. Am Heart J 1999 Feb; 137 (2): 307–12PubMedCrossRefGoogle Scholar
  61. 61.
    Lau E, Bungard TJ, Tsuyuki RT. Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc 2004 Mar; 52 (3): 428–33PubMedCrossRefGoogle Scholar
  62. 62.
    Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998 Oct 26; 158 (19): 2093–100PubMedCrossRefGoogle Scholar
  63. 63.
    Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003 Sep 22; 163 (17): 2052–7PubMedCrossRefGoogle Scholar
  64. 64.
    Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003 Oct 13; 163 (18): 2165–72PubMedCrossRefGoogle Scholar
  65. 65.
    Ryan C, O’Mahony D, Kennedy J, et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009 Dec; 68 (6): 936–47PubMedCrossRefGoogle Scholar
  66. 66.
    Barry PJ, Gallagher P, Ryan C, et al. START (screening tool to alert doctors to the right treatment): an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing 2007 Nov; 36 (6): 632–8PubMedCrossRefGoogle Scholar
  67. 67.
    Parsons C, Lapane K, Kerse N, et al. Prescribing for older people in nursing homes: a review of the key issues. Int J Older People Nurs 2011 Mar; 6 (1): 45–54PubMedCrossRefGoogle Scholar
  68. 68.
    Ruths S, Straand J, Nygaard HA. Multidisciplinary medication review in nursing home residents: what are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) Study. Qual Saf Health Care 2003 Jun; 12 (3): 176–80PubMedCrossRefGoogle Scholar
  69. 69.
    Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc 2010 May; 58 (5): 880–8PubMedCrossRefGoogle Scholar
  70. 70.
    Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009 Jan; 85 (1): 103–7PubMedCrossRefGoogle Scholar
  71. 71.
    Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006 Mar 27; 166 (6): 605–9PubMedCrossRefGoogle Scholar
  72. 72.
    Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007 Mar 21; 297 (11): 1233–40Google Scholar
  73. 73.
    Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol 2004 Jan; 57 (1): 86–92PubMedCrossRefGoogle Scholar
  74. 74.
    Pedone C, Lapane KL. Generalizability of guidelines and physicians’ adherence: case study on the Sixth Joint National Committee’s guidelines on hypertension. BMC Public Health 2003 Jul 21; 3: 24PubMedCrossRefGoogle Scholar
  75. 75.
    Agarwal G, Nair K, Cosby J, et al. GPs’ approach to insulin prescribing in older patients: a qualitative study. Br J Gen Pract 2008 Aug; 58 (553): 569–75PubMedCrossRefGoogle Scholar
  76. 76.
    Fernando P, Crome P. Combating age discrimination: a United kingdom perspective. EGM 2011; 2: 263–9Google Scholar
  77. 77.
    Barakat K, Wilkinson P, Deaner A, et al. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 1999 Mar 20; 353 (9157): 955–9PubMedCrossRefGoogle Scholar
  78. 78.
    Zaidi AM, Fitzpatrick AP, Keenan DJ, et al. Good outcomes from cardiac surgery in the over 70s. Heart 1999 Aug; 82 (2): 134–7PubMedGoogle Scholar
  79. 79.
    Conaway DG, House J, Bandt K, et al. The elderly: health status benefits and recovery of function one year after coronary artery bypass surgery. J Am Coll Cardiol 2003 Oct 15; 42 (8): 1421–6PubMedCrossRefGoogle Scholar
  80. 80.
    Harries C, Forrest D, Harvey N, et al. Which doctors are influenced by a patient’s age? A multi-method study of angina treatment in general practice, cardiology and gerontology. Qual Saf Health Care 2007 Feb; 16 (1): 23–7PubMedCrossRefGoogle Scholar
  81. 81.
    Zimmer AW, Calkins E, Hadley E, et al. Conducting clinical research in geriatric populations. Ann Intern Med 1985 Aug; 103 (2): 276–83PubMedCrossRefGoogle Scholar
  82. 82.
    Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991 Nov; 39 (11): 1093–9PubMedGoogle Scholar
  83. 83.
    Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000 Aug 1; 109 (2): 87–94PubMedCrossRefGoogle Scholar
  84. 84.
    Zopf Y, Rabe C, Neubert A, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol 2008 Oct; 64 (10): 999–1004PubMedCrossRefGoogle Scholar
  85. 85.
    Pedone C, Corsonello A, Carosella L, et al. Comparison of digitalis-related adverse events in hospitalized men and women in Italy: an observational study. Clin Ther 2005 Dec; 27 (12): 1922–9PubMedCrossRefGoogle Scholar
  86. 86.
    Rahimi AR, Spertus JA, Reid KJ, et al. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA 2007 Mar 14; 297 (10): 1063–72PubMedCrossRefGoogle Scholar
  87. 87.
    Choudhry NK, Patrick AR, Antman EM, et al. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 2008 Mar 11; 117 (10): 1261–8PubMedCrossRefGoogle Scholar
  88. 88.
    Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with cardiovascular disease who underuse medications because of cost: a longitudinal analysis. Med Care Feb; 2010; 48 (2): 87–94Google Scholar
  89. 89.
    Reuben DB. Medical care for the final years of life: “When you’re 83, it’s not going to be 20 years”. JAMA 2009 Dec 23; 302 (24): 2686–94PubMedCrossRefGoogle Scholar
  90. 90.
    Steinman MA, Hanlon JT. Managing medications in clinically complex elders: “There’s got to be a happy medium”. JAMA 2010 Oct 13; 304 (14): 1592–601PubMedCrossRefGoogle Scholar
  91. 91.
    Landi F, Onder G, Cesari M, et al. Pain management in frail, community-living elderly patients. Arch Intern Med 2001 Dec 10–24; 161 (22): 2721–4PubMedCrossRefGoogle Scholar
  92. 92.
    Won A, Lapane K, Gambassi G, et al. Correlates and management of nonmalignant pain in the nursing home. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. J Am Geriatr Soc 1999 Aug; 47 (8): 936–42PubMedGoogle Scholar
  93. 93.
    Smalbrugge M, Jongenelis LK, Pot AM, et al. Pain among nursing home patients in the Netherlands: prevalence, course, clinical correlates, recognition and analgesic treatment: an observational cohort study. BMC Geriatr 2007; 7: 3Google Scholar
  94. 94.
    Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009 Jan; 40 (1): 235–40PubMedCrossRefGoogle Scholar
  95. 95.
    Pisters R, van Oostenbrugge RJ, Knottnerus IL, et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace 2010 Jun; 12 (6): 779–84PubMedCrossRefGoogle Scholar
  96. 96.
    Beer C, Hyde Z, Almeida OP, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol 2011 Apr; 71 (4): 592–9PubMedCrossRefGoogle Scholar
  97. 97.
    Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med 2004 Mar 15; 116 (6): 394–401PubMedCrossRefGoogle Scholar
  98. 98.
    Spinewine A, Swine C, Dhillon S, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc 2007 May; 55 (5): 658–65PubMedCrossRefGoogle Scholar
  99. 99.
    Tulner LR, van Campen JP, Frankfort SV, et al. Changes in under-treatment after comprehensive geriatric assessment: an observational study. Drugs Aging 2010 Oct 1; 27 (10): 831–43PubMedCrossRefGoogle Scholar
  100. 100.
    Bajorek BV, Krass I, Ogle SJ, et al. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc 2005 Nov; 53 (11): 1912–20PubMedCrossRefGoogle Scholar
  101. 101.
    Lipton HL, Bero LA, Bird JA, et al. The impact of clinical pharmacists’ consultations on physicians’ geriatric drug prescribing: a randomized controlled trial. Med Care 1992 Jul; 30 (7): 646–58PubMedCrossRefGoogle Scholar
  102. 102.
    Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65: a randomized, controlled trial in primary care. Age Ageing 2001 May; 30 (3): 205–11PubMedCrossRefGoogle Scholar
  103. 103.
    Zermansky AG, Alldred DP, Petty DR, et al. Clinical medication review by a pharmacist of elderly people living in care homes: randomised controlled trial. Age Ageing 2006 Nov; 35 (6): 586–91PubMedCrossRefGoogle Scholar
  104. 104.
    Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm 2008 Nov–Dec; 14 (9): 831–43PubMedGoogle Scholar
  105. 105.
    Majumdar SR, Beaupre LA, Harley CH, et al. Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med 2007 Oct 22; 167 (19): 2110–5PubMedCrossRefGoogle Scholar
  106. 106.
    Feldstein A, Elmer PJ, Smith DH, et al. Electronic medical record reminder improves osteoporosis management after a fracture: a randomized, controlled trial. J Am Geriatr Soc 2006 Mar; 54 (3): 450–7PubMedCrossRefGoogle Scholar
  107. 107.
    Davis JC, Guy P, Ashe MC, et al. HipWatch: osteoporosis investigation and treatment after a hip fracture: a 6-month randomized controlled trial. J Gerontol A Biol Sci Med Sci 2007 Aug; 62 (8): 888–91PubMedCrossRefGoogle Scholar
  108. 108.
    Little EA, Eccles MP. A systematic review of the effectiveness of interventions to improve post-fracture investigation and management of patients at risk of osteoporosis. Implement Sci 2010; 5: 80PubMedCrossRefGoogle Scholar
  109. 109.
    Jackson SL, Peterson GM, Vial JH. A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother 2004 Nov; 38 (11): 1794–9PubMedCrossRefGoogle Scholar
  110. 110.
    Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther Jun; 2011; 89 (6): 845–54CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Antonio Cherubini
    • 1
    • 2
    Email author
  • Andrea Corsonello
    • 3
  • Fabrizia Lattanzio
    • 4
  1. 1.Italian National Research Centres on Aging (INRCA)Geriatric HospitalAnconaItaly
  2. 2.Institute of Gerontology and GeriatricsUniversity of Perugia Medical SchoolPerugiaItaly
  3. 3.Unit of Geriatric PharmacoepidemiologyItalian National Research Centre on Aging (INRCA)CosenzaItaly
  4. 4.Scientific DirectionItalian National Research Centres on Aging (INRCA)AnconaItaly

Personalised recommendations